Short Term Rating on Infinity Pharmaceuticals (INFI)

Infinity Pharmaceuticals (INFI) has an average broker rating of 3, which is interpreted as a Hold, as rated by 8 equity analysts. Nevertheless, the majority of 8 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Infinity Pharmaceuticals (INFI) : Currently there are 5 street experts covering Infinity Pharmaceuticals (INFI) stock. The most bullish and bearish price target for the stock is $2 and $1 respectively for the short term. The average price target of all the analysts comes to $1.65. The estimated standard deviation from the target is $0.49.

Company shares have received an average consensus rating of Hold for the current week


Infinity Pharmaceuticals (NASDAQ:INFI): The stock was completely flat for the day, closing at $1.42 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $1.40, the stock touched an intraday high of $1.44 and a low of $1.37. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.42. The total trading volume on Tuesday was 1,075,188.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *